Phase 2/3 study of peretinoin for the treatment of hepatocellular carcinoma (HCC)

Kowa announced the results of subgroup analyses from its Phase 2/3 study of peretinoin for its suppressive efficacy on recurrence of hepatocellular carcinoma (HCC). This trial evaluated the ability of peretinoin to suppress the recurrence of HCC in patients who had undergone curative therapy for hepatitis C virus (HCV) positive HCC. The analyses were performed in two subgroups (patients with mild (Child-Pugh A) liver impairment or patients with Child-Pugh A impairment with a major tumor diameter of less than 20mm prior to the curative therapy). In these subgroups, peretinoin 600mg/day showed a significantly greater reduction in the risk of HCC recurrence or death (the primary endpoint) compared to placebo.

Peretinoin is an oral acyclic retinoid with a vitamin A-like structure, and its main targeting molecule is the retinoid nuclear receptor.

For more information call (334) 288-1288 or visit www.kowapharma.com.